Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
Boehringer Ingelheim terminates contract with Hanmi Pharma
By 정민경Published : Sept. 30, 2016 - 10:44
[DISCLOSURE] Hanmi Pharmaceutical (128940) said on Sept. 30 that the contract regarding its lung cancer treatment HM61713 with German pharmaceutical firm, Boehringer Ingelheim has been terminated.
The German company will be returning its license obtained in 2015, but Hanmi Pharma is not obligated to refund the contract fee worth US$65 million.
(theinvestor@heraldcorp.com)
The German company will be returning its license obtained in 2015, but Hanmi Pharma is not obligated to refund the contract fee worth US$65 million.
(theinvestor@heraldcorp.com)
